For Healthcare Professionals Outside the US

KISQALI is indicated for the treatment of women with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)—negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy. In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone‑releasing hormone (LHRH) agonist.

HR+/HER2- metastatic breast cancer is a

How can your first-line treatment decision make all the difference?

After diagnosis of HR+/HER2– metastatic breast cancer, strength comes first

For premenopausal women taking first-line KISQALI

THE DIFFERENCE ISSUPERIOR OVERALL SURVIVAL

The only CDK4/6 inhibitor proven to help women with HR+/HER2— mBC live longer1,2

Explore the evidence
NEW OVERALL
SURVIVAL DATA
Discover more
QUALITY OF LIFE DATA
Discover more
WHAT EXPERTS SAY

about the new OS data

See videos

Superior overall survival was established in the MONALEESA-7 trial, comparing KISQALI and endocrine therapy vs placebo and endocrine therapy.1

CDK, cyclin-dependent kinase; mBC, metastatic breast cancer; OS, overall survival.

References: 1. Data on file. Novartis Pharma AG. 2. Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379(20):1926-1936.